A Long-Term, Open-Label Study to Evaluate the Safety and Tolerability of Brexpiprazole as Maintenance Treatment in Adults with Schizophrenia

International Journal of Neuropsychopharmacology

Volumn 21, Issue 5, 2018, Pages 433-441

  Forbes, Andy ^a   Hobart, Mary ^a   Ouyang, John ^a   Shi, Lily ^a   Pfister, Stephanie ^a   Hakala, Mika ^b  

^a OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^b H LUNDBECK A S   (Denmark)

Author keywords

brexpiprazole; long term; open label; schizophrenia

Indexed keywords

BREXPIPRAZOLE; GLUCOSE; PLACEBO; PROLACTIN; NEUROLEPTIC AGENT; QUINOLONE DERIVATIVE; THIOPHENE DERIVATIVE;

ABNORMAL INVOLUNTARY MOVEMENT SCALE; ADULT; AGED; AGITATION; AKATHISIA; ANXIETY DISORDER; ARTICLE; BODY MASS; BODY WEIGHT; CONTROLLED STUDY; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DSM-IV-TR; FATIGUE; FEMALE; GESTATIONAL AGE; HEADACHE; HUMAN; HYPERSOMNIA; INCIDENCE; INSOMNIA; LABORATORY TEST; LONG TERM CARE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; MONOTHERAPY; MULTICENTER STUDY; OBESITY; OPEN STUDY; OUTCOME ASSESSMENT; PHYSICAL EXAMINATION; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; SCHIZOPHRENIA; SEDATION; SOMNOLENCE; CLINICAL TRIAL; MIDDLE AGED; PHASE 3 CLINICAL TRIAL; SECONDARY PREVENTION;

ADULT; ANTIPSYCHOTIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); QUINOLONES; SCHIZOPHRENIA; SECONDARY PREVENTION; THIOPHENES;

EID: 85047249287     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1093/ijnp/pyy002     Document Type: Article

References (36)

1. American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders. 4th ed., text revision (DSM-IV-TRR). Washington, DC: American Psychiatric Association.
2. Bak M, Fransen A, Janssen J, van Os J, Drukker M (2014) Almost all antipsychotics result in weight gain: a meta-analysis. PLoS One 9: e94112.
3. Barnes TR (1989) A rating scale for drug-induced akathisia. Br J Psychiatry 154: 672-676.
4. Burns T, Patrick D (2007) Social functioning as an outcome measure in schizophrenia studies. Acta Psychiatr Scand 116: 403-418.
5. Chrzanowski WK, Marcus RN, Torbeyns A, Nyilas M, McQuade RD (2006) Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine. Psychopharmacology (Berl) 189: 259-266.
6. Citrome L (2012) Oral antipsychotic update: a brief review of new and investigational agents for the treatment of schizophrenia. CNS Spectr 17 (Suppl 1): 1-9.
7. Citrome L (2013) A review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: an evidence-based medicine approach. CNS Drugs 27: 879-911.
8. Citrome L (2017) Activating and sedating adverse effects of second-generation antipsychotics in the treatment of schizophrenia and major depressive disorder: absolute risk increase and number needed to harm. J Clin Psychopharmacol 37: 138-147.
9. Citrome L, Weiden PJ, McEvoy JP, Correll CU, Cucchiaro J, Hsu J, Loebel A (2014) Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study. CNS Spectr 19: 330-339.
10. Citrome L, Ota A, Nagamizu K, Perry P, Weiller E, Baker RA (2016) The effect of brexpiprazole (OPC-34712) and aripiprazole in adult patients with acute schizophrenia: results from a randomized, exploratory study. Int Clin Psychopharmacol 31: 192-201.
11. Correll CU (2011) What are we looking for in new antipsychotics? J Clin Psychiatry 72 (Suppl 1): 9-13.
12. Correll CU, Skuban A, Ouyang J, Hobart M, Pfister S, McQuade RD, Nyilas M, Carson WH, Sanchez R, Eriksson H (2015) Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled trial. Am J Psychiatry 172: 870-880.
13. Cutler AJ, Durgam S, Wang Y, Migliore R, Lu K, Laszlovszky I, Nemeth G (2017) Evaluation of the long-term safety and tolerability of cariprazine in patients with schizophrenia: results from a 1-year open-label study. CNS Spectr. May 8: 1-12. doi: 10. 1017/S1092852917000220. [Epub ahead of print]
14. Durgam S, Greenberg WM, Li D, Lu K, Laszlovszky I, Nemeth G, Migliore R, Volk S (2017) Safety and tolerability of cariprazine in the long-term treatment of schizophrenia: results from a 48-week, single-arm, open-label extension study. Psychopharmacology (Berl) 234: 199-209.
15. Fleischhacker WW, Hobart M, Ouyang J, Forbes A, Pfister S, McQuade RD, Carson WH, Sanchez R, Nyilas M, Weiller E (2017) Efficacy and safety of brexpiprazole (OPC-34712) as maintenance treatment in adults with schizophrenia: a randomized, double-blind, placebo-controlled study. Int J Neuropsychopharmacol 20: 11-21.
16. Guy W (1976) ECDEU assessment manual for psychopharmacology, revised. Rockville, MD: National Institute of Mental Health.
17. Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Thibaut F, Moller HJ, WFSBP Task Force on Treatment Guidelines for Schizophrenia (2013) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry 14: 2-44.
18. Kane JM, Skuban A, Ouyang J, Hobart M, Pfister S, McQuade RD, Nyilas M, Carson WH, Sanchez R, Eriksson H (2015) A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia. Schizophr Res 164: 127-135.
19. Kasper S, Lerman MN, McQuade RD, Saha A, Carson WH, Ali M, Archibald D, Ingenito G, Marcus R, Pigott T (2003) Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol 6: 325-337.
20. Kay SR, Fiszbein A, Opler LA (1987) The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 13: 261-276.
21. Lecrubier Y, Perry R, Milligan G, Leeuwenkamp O, Morlock R (2007) Physician observations and perceptions of positive and negative symptoms of schizophrenia: a multinational, crosssectional survey. Eur Psychiatry 22: 371-379.
22. Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, Kreyenbuhl J, American Psychiatric Association, Steering Committee on Practice Guidelines (2004) Practice guideline for the treatment of patients with schizophrenia. 2nd ed. Am J Psychiatry 161: 1-56.
23. Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Salanti G, Davis JM (2012) Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet 379: 2063-2071.
24. Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR, Kissling W, Stapf MP, Lassig B, Salanti G, Davis JM (2013) Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 382: 951-962.
25. Maeda K, Sugino H, Akazawa H, Amada N, Shimada J, Futamura T, Yamashita H, Ito N, McQuade RD, Mork A, Pehrson AL, Hentzer M, Nielsen V, Bundgaard C, Arnt J, Stensbol TB, Kikuchi T (2014) Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther 350: 589-604.
26. Marder SR, Davis JM, Chouinard G (1997) The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry 58: 538-546.
27. Montoya A, Valladares A, Lizan L, San L, Escobar R, Paz S (2011) Validation of the Excited Component of the Positive and Negative Syndrome Scale (PANSS-EC) in a naturalistic sample of 278 patients with acute psychosis and agitation in a psychiatric emergency room. Health Qual Life Outcomes 9: 18.
28. Morosini PL, Magliano L, Brambilla L, Ugolini S, Pioli R (2000) Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand 101: 323-329.
29. Nasrallah HA (2008) Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry 13: 27-35.
30. Nasrallah H, Morosini P, Gagnon DD (2008) Reliability, validity and ability to detect change of the Personal and Social Performance scale in patients with stable schizophrenia. Psychiatry Res 161: 213-224.
31. Nelson JC, Zhang P, Skuban A, Hobart M, Weiss C, Weiller E, Thase ME (2016) Overview of short-term and long-term safety of brexpiprazole in patients with major depressive disorder and inadequate response to antidepressant treatment. Curr Psychiatry Rev 12: 278-290.
32. Owen MJ, Sawa A, Mortensen PB (2016) Schizophrenia. Lancet 388: 86-97.
33. Pinna F, Tusconi M, Bosia M, Cavallaro R, Carpiniello B, Cagliari Recovery Group Study (2013) Criteria for symptom remission revisited: a study of patients affected by schizophrenia and schizoaffective disorders. BMC Psychiatry 13: 235.
34. Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, Currier GW, Melvin GA, Greenhill L, Shen S, Mann JJ (2011) The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry 168: 1266-1277.
35. Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Lobos CA, Kissling W, Davis JM, Leucht S (2010) Headto-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res 123: 225-233.
36. Simpson GM, Angus JWS (1970) A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 212: 11-19.